North America Novel Drug Delivery Systems Market- Growth, Trends, and Forecasts (2020 – 2025)

The North America Novel Drug Delivery Systems Market is segmented by Route of Administration, Mode of NDDS(Targeted Drug Delivery Systems, Controlled Drug Delivery Systems, Modulated Drug Delivery Systems) and Geography.

Market Snapshot

Study Period: 2017-2025
Base Year: 2019
CAGR: 5.8 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The major factors for the growth of the market include the growing need of controlled release of drugs, and technological advancements promoting the development of NDDS. Most of the drugs have an optimum concentration range and requirement of controlled release of drugs in the body. Concentrations above or below the prescribed range can be toxic or can produce no therapeutic benefits. Transdermal patches, nasal systems, microcapsules, etc., are some of the common systems that are considered under the controlled release systems. Hence, the requirement of the controlled release of drugs drives the novel drug delivery systems market. The stability of a delivery system is one of the most important factors that affect the drug delivery systems market. The restraining factors include stringent regulatory guidelines and product recalls.

Scope of the Report

As per the scope of this report, the novel drug delivery system (NDDS) is intended to increase the efficacy of drugs. NDDSs are adopted to increase the bioavailability of the drug, to reduce adverse effects and side effects, and increase drug stability. The market is segmented by route of administration, mode of NDDS, and geography.

By Route of Administration
Oral Drug Delivery Systems
Injectable Drug Delivery Systems
Pulmonary Drug Delivery Systems
Transdermal Drug Delivery Systems
By Mode of NDDS
Targeted Drug Delivery Systems
Controlled Drug Delivery Systems
Modulated Drug Delivery Systems
North America
United States

Report scope can be customized per your requirements. Click here.

Key Market Trends

Oral Drug Delivery Systems is Expected to Grow Fastest during the Forecast Period

Oral drug delivery has found to be the most preferred and convenient route of drug administration, due to high patient compliance, cost-effectiveness, least sterility constraints, flexibility in the design of dosage form, and ease of production. In oral administration, drugs should be protected under unstable biological environments, including drug degradation induced by the GI tract and first-pass liver effects after oral administration before reaching the targeted sites. The oral drug delivery is majorly driven by the increasing incidence of chronic diseases, reformulation and repositioning of drugs using advanced oral delivery systems, and huge investments made by big pharmaceutical companies on in-house capabilities for the development of oral drug delivery technologies. According to Globocan, 2018 there were a total of 2,129,118 incident cancers in the United States for the year 2018.

North America cancer cases.webp

To understand key trends, Download Sample Report

Competitive Landscape

The market players are focusing on the development of innovative treatment options in order to grab maximum market share. Some of the market players are Abbott Laboratories, AstraZeneca PLC, Bayer AG, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Sanofi SA

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Need of Controlled Release of Drugs

      2. 4.2.2 Technological Advancements Promoting Development of NDDS

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulatory Guidelines and Product Recalls

      2. 4.3.2 Stability Issues of the Devices

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Route of Administration

      1. 5.1.1 Oral Drug Delivery Systems

      2. 5.1.2 Injectable Drug Delivery Systems

      3. 5.1.3 Pulmonary Drug Delivery Systems

      4. 5.1.4 Transdermal Drug Delivery Systems

      5. 5.1.5 Others

    2. 5.2 By Mode of NDDS

      1. 5.2.1 Targeted Drug Delivery Systems

      2. 5.2.2 Controlled Drug Delivery Systems

      3. 5.2.3 Modulated Drug Delivery Systems

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico


    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 AstraZeneca PLC

      3. 6.1.3 Bayer Healthcare Pharmaceuticals

      4. 6.1.4 GlaxoSmithKline PLC

      5. 6.1.5 Johnson & Johnson

      6. 6.1.6 Novartis AG

      7. 6.1.7 Merck & Co.

      8. 6.1.8 Sanofi SA

      9. 6.1.9 Roche Holding AG

      10. 6.1.10 Pfizer Inc.

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The North America Novel Drug Delivery Systems (NDDS) Market market is studied from 2017 - 2025.

The North America Novel Drug Delivery Systems (NDDS) Market is growing at a CAGR of 5.8% over the next 5 years.

Abbott Laboratories, Roche Holding AG, Merck & Co., GlaxoSmithKline PLC, Bayer AG are the major companies operating in North America Novel Drug Delivery Systems (NDDS) Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!